Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease

Yang Jiao; Si-wei Li; Qing-hua Shang; Chang-geng Fu; Zhu-ye Gao; Hao Xu; Da-zhuo Shi; Ke-ji Chen

doi:10.1007/s11655-014-1831-5

Your Location：

Home >

Browse articles >

Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease

OriginalPaper | Updated：2021-08-27

- Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease
- Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease
- 中国结合医学杂志（英文版） 2014年20卷第5期页码：341-346
- Affiliations：
  
  1. Graduate School, Beijing University of Chinese Medicine,Beijing,China
  2. Center for Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by Beijing Committee of Science and Technology (No. D08050703020801), the Traditional Chinese Medicine Public Welfare Scientific Research Project, State Administration of Traditional Chinese Medicine of People’s Republic of China (No. 201007001), Natural Science Foundation of China (No. 30973702, 81373823, 81030063), and National Major Project for Fundamental Research and Development (No. 2006CB504803);Contribute equally to this paper
- DOI：10.1007/s11655-014-1831-5
  中图分类号：
- 纸质出版日期：2014，
  
  网络出版日期：2014-3-6，
Scan for full text
Jiao, Y., Li, Sw., Shang, Qh. et al. Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease., Chin. J. Integr. Med. 20, 341–346 (2014). https://doi.org/10.1007/s11655-014-1831-5

Yang Jiao, Si-wei Li, Qing-hua Shang, et al. Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease[J]. Chinese Journal of Integrative Medicine, 2014,20(5):341-346.
Jiao, Y., Li, Sw., Shang, Qh. et al. Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease., Chin. J. Integr. Med. 20, 341–346 (2014). https://doi.org/10.1007/s11655-014-1831-5 DOI：

Yang Jiao, Si-wei Li, Qing-hua Shang, et al. Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease[J]. Chinese Journal of Integrative Medicine, 2014,20(5):341-346. DOI： 10.1007/s11655-014-1831-5.

摘要

To analyze the correlation of Chinese medicine syndrome evolvement and cardiovascular: events in patients with stable coronary heart disease (CHD). This prospective cohort study investigated and: collected the clinical information of patients with stable CHD and observed the syndrome type at the baseline and 6-month at follow-up

as well as the cardiovascular events during the 6-month and 12-month follow-up. The patients were divided into the event group and the non-event group. The interaction and the impact of syndrome evolvement on cardiovascular events were examined through multifactor dimensionality reduction (MDR) analysis and the results were verified by Chi-square test. Totally 1

333 of 1

503 stable CHD patients enrolled met the inclusion criteria: of MDR analysis. Among them

959 (71.9%) cases were males and 374 (28.1%) cases were females. Thirty seven cases had cardiovascular events during 6 to 12 months after the study began. The results of the MDR analysis and verification using Chi-square test showed that the development of cardiovascular events was positively correlated with interaction between blood stasis and toxic syndrome at the baseline

blood stasis at the baseline and qi deficiency at the 6-month follow-up

toxic syndrome at the baseline and qi deficiency at the 6-month follow-up

toxic syndrome at the base line and blood stasis at the 6-month follow-up

qi deficiency and blood stasis at the 6-month follow-up (P<0.05 for all). Blood stasis

toxic syndrome and qi deficiency are important factors of stable CHD. There: are positive correlation between cardiovascular events and syndrome evolution from blood stasis to qi deficiency

from toxic syndrome to qi deficiency and from toxic syndrome to blood stasis

indicating the pathogenesis of toxin consuming qi

toxin leading to blood-stasis in stable CHD patients prone to recurrent cardiovascular events.

Abstract

333 of 1

503 stable CHD patients enrolled met the inclusion criteria: of MDR analysis. Among them

blood stasis at the baseline and qi deficiency at the 6-month follow-up

toxic syndrome at the baseline and qi deficiency at the 6-month follow-up

toxic syndrome at the base line and blood stasis at the 6-month follow-up

qi deficiency and blood stasis at the 6-month follow-up (P<0.05 for all). Blood stasis

toxic syndrome and qi deficiency are important factors of stable CHD. There: are positive correlation between cardiovascular events and syndrome evolution from blood stasis to qi deficiency

from toxic syndrome to qi deficiency and from toxic syndrome to blood stasis

indicating the pathogenesis of toxin consuming qi

toxin leading to blood-stasis in stable CHD patients prone to recurrent cardiovascular events.

关键词

stable coronary heart diseasecardiovascular eventssyndrome evolvementpathogenesis characteristics

Keywords

stable coronary heart diseasecardiovascular eventssyndrome evolvementpathogenesis characteristics

references

Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–1435.

Sedlis SP, Jurkovitz CT, Hartigan PM, Kolm P, Goldfarb DS, Lorin JD, et al. COURAGE Study Investigators. Health status and quality of life in patients With stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial). Am J Cardiol 2013;112:1703–1708.

Boden WE, O’Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, et al. COURAGE Trial Investigators.Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol 2009;104:1–4.

Pfisterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. Lancet 2010;375:763–772.

Yu G, Wang J. Blood stasis syndrome of coronary heart disease: a perspective of modern medicine. Chin J Integr Med 2013 Jul 27. [Epub ahead of print]

Chen KJ. Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy. Chin J Integr Med 2012;18:891–896.

Cardiovascular Specialty Committee, China Association of Integrative Medicine. Criterion of syndrome differentiation for CHD. Chin J Integr Tradit West Med (Chin) 1991;11:257.

Chen KJ, Shi DZ, Xu H, Yin HJ, Zhang JC. Ecchymosis mutagenic diagnostic quantitative criteria in Patients with stable coronary artery disease. Chin J Integr Tradit West Med (Chin) 2011;31:313–314.

Liu BY, Zhou XZ, Li P, Wang YH, Wen TC, Guo YF, et al. Individual treatment information integration platform for clinical research. China Digital Med (Chin) 2007;2:31–36.

Zhou XZ, Chen SB, Liu BY, Zhang, RS, Wang YH, Li P, et al. Development of traditional Chinese medicine clinical data warehouse for medical knowledge discovery and decision support. Artif Intell Med 2010;48:139–152.

Zhou XZ, Zhang RS, Shah J, Rajgor D, Wang YH, Pietrobon R, et al. Patterns of herbal combination for the treatment of insomnia commonly employed by highly experienced Chinese medicine physicians. Chin J Integr Med 2011;17:655–662.

Chen Q, Tang X, Hu YH. Detecting interaction for quantitative trait by generalized multifactor dimensionality reduction. Chin J Chromatogr (Chin) 2010;31:938–941.

Winham S. Applications of multifactor dimensionality reduction to genome-wide data using the R package ‘MDR’. Methods. Mol Biol 2013;1019:479–498.

Wu Y, Zhang L, Liu L, Zhang Y, Zhao Z, Liu X, et al. A multifactor dimensionality reduction-logistic regression model of gene polymorphisms and an environmental interaction analysis in cancer research. Asian Pac J Cancer Prev 2011;12:2887–2892.

Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138–147.

Coffey CS, Hebert PR, Ritchie MD, Krumholz HM, Gaziano JM, Ridker PM, et al. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. BMC Bioinformatics 2004;5:49.

FULL TEXT LINK

More>

浏览量

756

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据